Glabellar Frown Lines

10 drugs in development·2 companies·8 clinical trials

Drug Pipeline by Phase

Phase 3(1)

Drug	Company
CU-20101 treatment for Moderate to Severe Glabellar Striae	Revance Therapeutics, Inc. (RVNC)

Phase 2(1)

Drug	Company
daxxify	Revance Therapeutics, Inc. (RVNC)

Unknown(1)

Drug	Company
prabotulinumtoxina	Evolus, Inc. (EOLS)

Phase 4(7)

Drug	Company
Botulinum Toxin A	Revance Therapeutics, Inc. (RVNC)
Botulinum Toxin A - Open Label	Revance Therapeutics, Inc. (RVNC)
onabotulinumtoxinA at a depth of 2mm	Revance Therapeutics, Inc. (RVNC)
onabotulinumtoxinA at a depth of 4mm	Revance Therapeutics, Inc. (RVNC)
onabotulinumtoxinA biosimilar	Revance Therapeutics, Inc. (RVNC)
OnabotulinumtoxinA X	Revance Therapeutics, Inc. (RVNC)
prabotulinumtoxinA	Revance Therapeutics, Inc. (RVNC)

BioSniper tracks 10 drugs in development for Glabellar Frown Lines across 2 companies.

There are 8 clinical trials targeting Glabellar Frown Lines tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.